Testosterone and MHT – Your questions answered

Expert/s: Dr James Brown
   Rated 0 / 5 stars

Save

CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

1 hours

These are activities that use your work data to ensure quality results.

EA
0.5 hours

Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 hours

Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.

MO
1 hours

Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.

Listen to the episode

Description

The questions answered in this podcast are listed below.
They were compiled by GPs and professional attendees at our face-to-face seminars around Australia.

  1. Can testosterone gel be prescribed to women with a history of provoked VTE?
  2. Can women use testosterone if not using MHT?
  3. Should estrogen levels be optimised first to determine whether symptoms such as low libido, brain fog and fatigue improve before considering testosterone? Can it also be safely trialled in premenopausal women?
  4. What testosterone level is considered too high in women?
  5. Should testosterone be ceased if serum testosterone levels are above the female reference range but the patient is asymptomatic?
  6. Do some women increase their testosterone dose to improve libido or sexual responsiveness?
  7. Can testosterone be trialled in a postmenopausal woman with low libido despite a normal testosterone level?
  8. How should GPs manage women who develop acne or hirsutism while using testosterone therapy?
  9. When should transdermal oestrogen be preferred over oral MHT?
  10. Is there an upper age limit for HRT or MHT, and does Livial or Tibolone fit into that equation?
  11. How do you decide when micronised progesterone needs to be increased in women using higher-dose Estrogel?
  12. Can Implanon be used as the progesterone component of MHT?
  13. When should cyclical progesterone be commenced during the cycle?
  14. How do you approach MHT in women who may still be cycling during the menopausal transition, and if breakthrough bleeding occurs on continuous MHT, what is your approach?
  15. Would you trial MHT in a healthy 65-year-old woman seeking dementia prevention?

 

Expert: Dr James Brown, Fertility Specialist & Gynaecologist

Host: Dr Rebecca Overton, GP & Medical Educator

Total time: 37 mins

 

Last Updated: 1 Oct, 2026

Rate this podcast
Help your colleagues find podcasts they'll enjoy by rating this podcast out of five stars.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

Expert panel – A/Prof Samantha Hocking & Dr Terri-Lynne South, facilitated by A/Prof Ralph Audehm

GLP 1s & Sarcopenia: Fact vs Hype

Dr Deb Mills

Dr Deb Mills

The New Dengue Vaccine – What You Need to Know

Dr Robert Hungerford

Dr Robert Hungerford

Hypertriglyceridaemia – Causes, Assessment & Management of CV Risk

A/Prof Michelle Rodrigues

A/Prof Michelle Rodrigues

Management of Photoageing

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

You have completed the Educational Activities (EA) component of this activity.

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.